Tikvah Management LLC, which owns approximately 1.5% of Quanterix Corp.'s common shares, issued a statement on April 14, 2025, calling on Quanterix to explain its recent purchase agreement for up to $30 million in convertible notes from Akoya Biosciences, Inc. Tikvah expressed concern for several reasons.
First, Tikvah believes Akoya’s need for bridge financing serves as a significant warning sign of its financial distress. Second, the firm found it unusual and coercive to Quanterix’s shareholders that this capital was committed before a shareholder vote on the proposed merger with Akoya.
Lastly, Tikvah stated that the terms of these convertible notes are significantly off-market and unfair to Quanterix shareholders. The firm reiterated its intention to vote AGAINST Quanterix’s proposed merger with Akoya at the upcoming Quanterix Special Meeting for shareholders.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.